CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home Search
Result Type
Evidence Bundles
Product Line
Body Systems
Disease and Conditions
Target Population
Technologies, Therapies and Systems
Testing and Diagnostics
Publication Date
Clear all filters

Reports

We found 6233 result(s)

tildrakizumab (Ilumya )

Last Updated: December 4, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tildrakizumab
Indications: Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  • Brand Name: Ilumya
  • Manufacturer: Sun Pharma Canada
  • Project Number: SR0624-000
  • Project Status: Active
  • Submission Type: Initial
Details

dupilumab (Dupixent)

Last Updated: December 3, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Received
  • Submission Type: Initial
Details

risdiplam (TBC)

Last Updated: December 3, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA)

  • Brand Name: TBC
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial
Details

ofatumumab (TBC)

Last Updated: December 3, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of Relapsing Multiple Sclerosis (RMS).

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-0000
  • Project Status: Active
  • Submission Type: Initial
Details

vedolizumab (Entyvio)

Last Updated: December 3, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: vedolizumab
Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Active
  • Submission Type: Initial
Details

dapagliflozin (Forxiga )

Last Updated: December 2, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dapagliflozin
Indications: ​Forxiga is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of CV death, hospitalization for heart failure and urgent heart failure visit, and to improve heart failure symptoms.

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: Initial
Details

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer Web Services

Last Updated: December 4, 2020
Result type: Reports
Product Line: Health Technology Assessment
Research Type: Device

Stereotactic ablative body radiotherapy (SABR) is a newer form of radiation treatment that delivers high-precision doses to specific body sites over a shorter treatment period than conventional radiotherapy. For cancer therapy, SABR is an alternative to surgical treatment and an option for non-surgical candidates as it does not require recovery ...

  • Project Number: HT0029-000
  • Project Status: In Progress
Details

Venetoclax (Venclexta)

Last Updated: December 3, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Venetoclax
Indications: In combination with azacitidine or low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

  • Brand Name: Venclexta
  • Manufacturer: AbbVie Corporation
  • Project Number: PC0238-000
  • Project Status: Pending
  • Submission Type: Initial
Details

durvalumab (Imfinzi)

Last Updated: December 2, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: durvalumab
Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

  • Brand Name: Imfinzi
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0234-000
  • Project Status: Received
  • Submission Type: Initial
Details

Implementation of Stereotactic Ablative Radiotherapy in Canada

Last Updated: December 3, 2020
Result type: Reports
Product Line: Environmental Scans

CADTH is undertaking an Environmental Scan to support a health technology assessment project regarding the use of stereotactic ablative radiotherapy (SABR) in Canada and to provide an understanding of the current practice regarding the use of SABR, as well as the implementation considerations for expanding the use of SABR for the treatment of ol...

  • Project Number: ES0352-000
Details